Navigation Links
CryoLife Posts Record Quarterly Revenues of $30.2 Million
Date:4/28/2011

dition, profitability, and cash flows, regulatory action outside of the U.S. has affected our business in the past and may affect our business in the future, rapid technological change could cause our services and products to become obsolete, continued fluctuation of foreign currencies relative to the U.S. Dollar could materially and adversely impact our business, our credit facility which expires in June 2011, but could be extended, limits our ability to pursue significant acquisitions, key growth strategies may not generate the anticipated benefits, our ability to borrow under our credit facility which expires in June 2011 may be limited, we may not be able to enter into a new credit facility after our current credit facility expires, we may not be successful in obtaining necessary clinical results and regulatory approvals for services and products in development, and our new services and products may not achieve market acceptance, investments in new technologies and acquisitions of products or distribution rights may not be successful, extensive government regulation may adversely affect our ability to develop and market services and products, if we are not successful in expanding our business activities in international markets, we may be unable to increase our revenues, we are not insured against all potential losses, and natural disasters or other catastrophes could adversely affect our business, we may be unable to obtain adequate insurance at a reasonable cost, if at all, and we are dependent on key personnel. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2010 and our Form 10-Q to be filed on or around April 28, 2011 for the quarter ended March 31, 2011.  CryoLife does not undertake to update its forward-looking statements.CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands, except per share d
'/>"/>
SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. CryoLife Launches BioGlue® Surgical Adhesive in Japan
2. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
3. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
4. CryoLife Commences Tender Offer for All Outstanding Shares of Cardiogenesis Corporation
5. CryoLife Signs Definitive Agreement to Acquire Cardiogenesis
6. CryoLife Posts Record Annual Revenues of $116.6 Million
7. CryoLife Announces Release Date and Teleconference Call Details for 2010 Fourth Quarter and Year End Financial Results
8. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
11. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015 ReportsnReports.com adds Global ... 2020 forecasts as well as Global Medical Simulation ... intelligence collection of its library. Complete ... forecasts spread across 164 pages, talking about 7 ... figures is now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html ...
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical Companies, ... call on Friday, August 7, 2015 at 9:00 a.m. ... second quarter ended June 30, 2015.  Par is privately ... the public in its filings with the Securities and ... on its website by following the instructions at ...
(Date:8/3/2015)... OmniSeq, LLC today announced the addition ... SM Genomic Network.  Recently, OmniSeq officially spun ... announced it was making available a suite of ... to genomic diagnostics that provides actionable results to ... rapidly expanding, multidisciplinary cancer care center that is ...
Breaking Medicine Technology:Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... - ARIAD,Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that ... 2 and,1b clinical data from ongoing trials of ... meeting of the American Society,of Clinical Oncology (ASCO) ... data from the Phase 2 trial of single-agent,AP23573 ...
... May 25, 2007 /PRNewswire-FirstCall/ --,Genta Incorporated announced that several ... (gallium nitrate injection), will be presented at the,43rd annual ... Chicago, June 1-5, 2007. The abstracts include the,following: , ... Factor in Stage IV Melanoma Patients but is a, ...
Cached Medicine Technology:Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 2Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 3Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting 4Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology 2Genta Incorporated to Present Multiple Abstracts at the Annual,Meeting of the American Society of Clinical Oncology 3
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to ... University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative ... Africa. , A cooperative agreement awarded by the U.S. Agency for International ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent ... for drugs, biologics and consumer health products, today welcomed the announcement by OPKO ... New Drug Application for a new treatment for chronic kidney disease (CKD) and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched the ... as well as announced the date of its next major release. , Version ... management tasks as well as enhancements to the customer experience. Users now ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato ... new program “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive ... healthcare organizations with access to the tactics, techniques and practices required to design ...
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
Breaking Medicine News(10 mins):Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... - When given alongside radiation therapy for head and ... to reduce the debilitating side effect of xerostomia, according ... Anderson Cancer Center and Fudan University Shanghai Cancer Center. ... , reported findings from the first randomized controlled trial ...
... press release is available in French . , ... metastasis has been identified by a team of researchers led by ... Health Centre (RI-MUHC). Complications in breast cancer patients are commonly caused ... of the body, most often to the bones and lungs. These ...
... Norwegians, the investigators found that alcohol consumption was associated ... from coronary artery disease. For men, the fully ... CI 0.39 - 0.69) when comparing subjects reporting more ... or rarely drinking; for women, it was 0.62 (0.3-.23). ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... , THURSDAY, Nov. 10 (HealthDay News) -- ,Heavy ... according to a new study. It also confirmed ... and schizophrenia. Methamphetamine and other amphetamine-type stimulants are ... worldwide. In this study, researchers at the Centre ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay ... livers are typically subject to a mandatory six-month "dry-out" ... Unfortunately, many of the sickest of these patients fail ... that earlier transplants can dramatically improve survival odds in ...
Cached Medicine News:Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 2Health News:UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth 3Health News:New target identified to stop the spread of breast cancer 2Health News:Flexible rack systems sort molecules 2Health News:Heavy Meth Use Linked to Schizophrenia 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 2Health News:Study Supports Shorter Wait Time for Alcoholics Seeking Liver Transplant 3
... From simple techniques such as submarine electrophoresis ... Step IEF, the Series 90 Programmable Power ... Series 90 Programmable Power Supplies are available ... or 6000V., All models operate in constant ...
... - 200: 200V, .01-2A. 300: 300V, 4-400mA. ... Select constant voltage or constant current ... gels. - Compact, lightweight and stackable. - ... - Ideal for DNA, RNA and protein ...
... The MAX POWER Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
Medicine Products: